Canopy Growth Corporation - Common Shares (CGC)

The next key catalyst for this cannabis stock lies in the hands of a U.S. Federal Government agency.

The president directed federal authorities to reschedule medical marijuana.

A lower stock price doesn't eliminate investment risk.

Shares of the cannabis company have fallen below the $1 mark again.

Be careful before bucking the bearish trend.

Canopy Growth's medical marijuana division had a great quarter, but the rest of the business wasn't so lucky.

Canopy Growth is a much riskier stock than it was five years ago.

Canopy Growth (NASDAQ:CGC) reported higher fiscal fourth-quarter revenue and said it entered fiscal 2027 with a stronger balance sheet following a year of restructuring, cost cuts and the acquisition of MTL Cannabis. On the company’s earnings call, Chief Executive Officer Luc Mongeau described fisc

It will likely be more of the same from here on out for this cannabis player.

Several key metrics point to improving fundamentals.

The move only shifted a certain category of weed.

When a company restates its earnings, it often indicates mistakes were made, which can be a troubling issue for a penny stock.

It's unfitting that the marijuana seller has "growth" in its name.

The cannabis company has reduced debt and stacked up cash, but profitability remains elusive.

After years of heavy losses and repeated restructurings, Canopy Growth is showing early signs of stabilization.

The pot stock is up over 30% in just the past month.

Canopy Growth shares are up 25% over the past month, but investors need to keep in mind where it started.

Canopy Growth Corp (NASDAQ:CGC) shares are falling Thursday, pulling back after Wednesday's rally on U.S. cannabis policy shift.

Shares of Canopy Growth (NASDAQ: CGC) are surging Wednesday afternoon following news of a potential major shift in federal cannabis policy.

Err on the side of caution with this falling knife.

The cannabis stock has lost around 96% of its value over the past five years.

Shares of Constellation Brands (NYSE: STZ) skyrocketed by 8.5% on April 10, 2026, marking one of the most significant single-day breakouts for the beverage giant in recent years. The rally, which propelled the stock to an all-time high, follows a week of robust financial disclosures and a series of

Tilray Brands (NASDAQ:TLRY) has officially transitioned from a volatile cannabis producer to a diversified global consumer packaged goods (CPG) powerhouse, reporting record-breaking Q3 fiscal 2026 results. The company posted net revenue of $207 million, a figure driven by a stunning recovery in its beverage segment and explosive growth in

NEW YORK — Tilray Brands, Inc. (NASDAQ:TLRY) delivered a resounding message to the market this week, reporting a record-breaking $206.7 million in net revenue for its fiscal 2026 third quarter. The results, released on April 1, 2026, showcase a company successfully navigating a complex global landscape by pivoting toward

In a paradoxical display of market confidence, shares of Tilray Brands (NASDAQ:TLRY) surged over 8% on Wednesday following the release of its fiscal third-quarter 2026 financial results. While the company delivered a "record" revenue performance of $206.7 million, outstripping analyst estimates of $201.3 million, it fell significantly